ARCHIVES

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

This article is from The Cancer Letter archive.

Vol. 23 No. 32 | August 15, 1997

Download PDF Visit The Full Archive

Related Articles

Texts Of Workshop Report Summarized

November 8, 1996

Changes In Clinical Trials Mechanism Inevitable, But NCI Says It will Heed Critics Of Proposals

April 18, 1986

Brachytherapy Better Than Surgery For Prostate Cancer

October 29, 2004

Senate Committee Approves Additional $400 Million For NCI, $275 Million For FDA.

May 16, 2008

With workload Up, Oncology Division To Add More Staff

August 2, 1996

Oncologists lose money administering drugs to Medicare patients, survey finds.

January 23, 2004